Product information and disease descriptionProduct descriptionProduct information
Special populations
9 evidence topics · 7 sources
Adolescents aged 12 to 17 years: eligibility and enrollment in the phase 3 trial
Children younger than 12 years: EU paediatric investigation plan
“Age appropriate oral solid dosage form” (opens the source at this quote in a new tab)
“Capsule, soft” (opens the source at this quote in a new tab)
“Prolonged-release tablet” (opens the source at this quote in a new tab)
“Treatment of hereditary angioedema” (opens the source at this quote in a new tab)
Older adults: upper age limit and participants aged 65 years or older in the phase 3 trial
| Age group | RAPIDe-3 enrolled participants (N = 134), n (%) |
|---|---|
| Aged 12 to younger than 18 years | “10 (7.5)” |
| Aged 18 to younger than 65 years | “116 (86.6)” |
| Aged 65 years or older | “8 (6.0)” |